Non-Alcoholic Steatohepatitis (NASH): Risk Factors in Morbidly Obese Patients-Reference-Cited by-同舟云学术

Non-Alcoholic Steatohepatitis (NASH): Risk Factors in Morbidly Obese Patients

Published:2015-10-23 Issue:10 Volume:16 Page:25552-25559
ISSN:1422-0067
Container-title:International Journal of Molecular Sciences
language:en
Short-container-title:IJMS

Author:

Losekann Alexandre,Weston Antonio,de Mattos Angelo,Tovo Cristiane,de Carli Luis,Espindola Marilia,Pioner Sergio,Coral Gabriela

Publisher

MDPI AG

Subject

Inorganic Chemistry,Organic Chemistry,Physical and Theoretical Chemistry,Computer Science Applications,Spectroscopy,Molecular Biology,General Medicine,Catalysis

Link

http://www.mdpi.com/1422-0067/16/10/25552/pdf

Reference27 articles.

1. Nonalcoholic steatohepatitis;Brunt;Semin. Liver Dis.,2004

2. Associations between nonalcoholic fatty liver disease and risk for hepatocellular cancer based on systematic review;White;Clin. Gastroenterol. Hepatol.,2012

3. Meta-analysis: Natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity

4. The epidemiology of nonalcoholic fatty liver disease in adults;Clark;J. Clin. Gastroenterol.,2006

5. Nonalcoholic steatohepatitis in nondiabetic obese patients;Zamin;Can. J. Gastroenterol.,2002

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Assessment of Metabolic and Bariatric Surgery Safety in Patients with Advanced Liver Fibrosis;Obesity Surgery;2024-07-30

2. Predictors of Nonalcoholic Steatohepatitis Severity in Obese Patients Undergoing Bariatric Surgery: A Cross-Sectional Study;Bariatric Surgical Practice and Patient Care;2023-12-01

3. The Effect of Roux-en-Y Gastric Bypass on Non-Alcoholic Fatty Liver Disease Fibrosis Assessed by FIB-4 and NFS Scores—An 11.6-Year Follow-Up Study;Journal of Clinical Medicine;2022-08-21

4. Fibromax and inflamatory markers cannot replace liver biopsy in the evaluation of non-alcoholic fatty liver disease;MINERVA GASTROENTERO;2022

5. Fibromax and inflamatory markers cannot replace liver biopsy in the evaluation of non-alcoholic fatty liver disease;Minerva Gastroenterology;2022-03